# BrainDB - 脑科学知识引擎

> Brain science knowledge base covering brain regions, BCI, neural implants, brain disorders, and neuropharmacology

## API Endpoints (JSON)

- `GET /api/data.json` - Complete structured data
- `GET /api/entities.json` - All entities flat list
- `GET /api/openapi.json` - OpenAPI 3.1 specification

## Stats

- Total entities: 252
- brain_regions: 72
- bci: 68
- neural_implants: 37
- brain_disorders: 38
- neuropharmacology: 37

## Categories

### brain_regions

- **Prefrontal Cortex**: The prefrontal cortex is the most recently evolved brain region and is responsible for higher cognitive functions. It comprises ~30% of the human cerebral cortex. Damage (e.g., Phineas Gage case) profoundly alters personality and decision-making. It is the last region to fully mature (~age 25) and is implicated in most psychiatric disorders.
- **Hippocampus**: The hippocampus is critical for forming new episodic and spatial memories. London taxi drivers famously have larger posterior hippocampi from navigation experience. It's one of the first regions damaged in Alzheimer's disease, explaining why memory loss is an early symptom. Adult neurogenesis occurs in the dentate gyrus, one of the few brain regions where new neurons are born throughout life.
- **Amygdala**: The amygdala is the brain's threat detection center, rapidly processing fear and danger signals before conscious awareness. It tags emotional memories, making them more vivid and lasting. Hyperactivity is linked to anxiety disorders and PTSD; hypoactivity to risk-taking and psychopathy. The amygdala is a key target for PTSD treatments including exposure therapy and MDMA-assisted therapy.
- **Cerebellum**: The cerebellum contains more neurons than the rest of the brain combined (~69 billion) despite being only 10% of brain volume. While traditionally associated with motor control, recent research reveals major roles in cognition, language, and emotion. Cerebellar abnormalities are found in autism, schizophrenia, and dyslexia. It's a target for non-invasive brain stimulation therapies.
- **Basal Ganglia**: The basal ganglia are a group of subcortical nuclei critical for selecting and initiating voluntary movements. Dopamine from the substantia nigra modulates basal ganglia circuits. Parkinson's disease results from loss of these dopamine neurons. The basal ganglia also drive habit formation and reward-based learning, making them central to addiction neuroscience.
- **Thalamus**: The thalamus is the brain's sensory relay station, routing nearly all sensory information (except olfaction) to the appropriate cortical areas. It also plays a crucial role in consciousness and the sleep-wake cycle. Thalamic lesions can cause severe chronic pain (thalamic pain syndrome) or disorders of consciousness. Deep brain stimulation of the thalamus treats essential tremor and some forms of epilepsy.
- **Hypothalamus**: The hypothalamus is the brain's master regulator of homeostasis, controlling the autonomic nervous system and pituitary gland. It regulates body temperature, hunger, thirst, sleep, and hormonal balance. The suprachiasmatic nucleus (SCN) is the body's master clock. Hypothalamic dysfunction can cause obesity, diabetes insipidus, and sleep disorders.
- **Insular Cortex (Insula)**: The insula is a hidden cortical region critical for interoception (sensing internal body states) and emotional self-awareness. It integrates bodily sensations with emotional and cognitive processing. The anterior insula is activated during empathy, disgust, and craving. The insula is increasingly recognized as a key hub in addiction (craving), anxiety, and chronic pain.
- **Default Mode Network (DMN)**: The DMN is a large-scale brain network active during rest and mind-wandering, deactivated during goal-directed tasks. It's critical for self-reflection, memory retrieval, and creative thinking. DMN dysfunction is implicated in numerous psychiatric and neurological conditions. DMN connectivity is increasingly used as a biomarker for brain health.
- **Ventral Tegmental Area (VTA)**: The VTA contains the brain's primary reward circuit dopamine neurons. These neurons signal prediction error - the difference between expected and received rewards - forming the basis of reinforcement learning. VTA dopamine release is hijacked by addictive drugs, making it central to addiction neuroscience.
- **Anterior Cingulate Cortex (ACC)**: The ACC monitors for errors and conflicts, signaling when adjustments are needed. It's crucial for the emotional component of pain (how much pain bothers you). The ACC is a target for deep brain stimulation in treatment-resistant depression and OCD. Damage can cause akinetic mutism (awake but unresponsive).
- **Substantia Nigra**: The substantia nigra contains dopamine neurons that project to the basal ganglia (nigrostriatal pathway). Loss of these neurons causes Parkinson's disease, with symptoms appearing after ~60% have died. The dark pigment (neuromelanin) gives it its name ('black substance'). Deep brain stimulation of downstream targets can alleviate Parkinson's motor symptoms.
- **Visual Cortex (V1-V5)**: The visual cortex processes visual information in a hierarchical stream. V1 performs basic feature extraction; higher areas process increasingly complex features (motion, color, faces, objects). The ventral stream (what) identifies objects; the dorsal stream (where/how) processes spatial relationships. Visual prostheses target V1 to restore vision in blindness.
- **Auditory Cortex**: The auditory cortex processes sound features from basic frequencies to complex speech and music. The left auditory cortex specializes in speech processing; the right in music and prosody. Cochlear implants stimulate the auditory nerve to bypass damaged hair cells. Auditory cortex abnormalities are linked to tinnitus and auditory hallucinations in schizophrenia.
- **Somatosensory Cortex**: The somatosensory cortex processes tactile and proprioceptive information from the body. It's organized as a 'homunculus' (body map) with disproportionate representation of hands and face. Phantom limb pain after amputation is related to cortical reorganization. Somatosensory BCIs are being developed to restore touch sensation in paralysis.
- **Motor Cortex (M1)**: The primary motor cortex (M1) generates neural signals that drive voluntary movement. It's organized as a motor homunculus with large representations for hands and face (fine motor control). M1 is the primary target for brain-computer interfaces that decode movement intentions for paralysis patients. Neuralink, BrainGate, and others record from M1 to restore communication and movement.
- **Broca's Area**: Broca's area is critical for speech production and grammatical processing. Damage causes Broca's aphasia: patients understand language but cannot produce fluent speech (telegraphic speech). Named after Paul Broca who studied patient 'Tan' in 1861. TMS to Broca's area can temporarily disrupt speech production, confirming its role.
- **Wernicke's Area**: Wernicke's area is essential for understanding spoken and written language. Damage causes Wernicke's aphasia: patients produce fluent but meaningless speech (word salad) and cannot comprehend language. The arcuate fasciculus connects Broca's and Wernicke's areas; damage to this pathway causes conduction aphasia (can speak and understand but cannot repeat).
- **Corpus Callosum**: The corpus callosum is the largest white matter tract, containing ~200 million axons connecting the two cerebral hemispheres. Split-brain patients (corpus callosotomy for epilepsy) revealed that each hemisphere has independent consciousness and specialized functions. The corpus callosum is affected early in multiple sclerosis and Alzheimer's disease.
- **Brainstem (Midbrain, Pons, Medulla)**: The brainstem controls vital autonomic functions necessary for survival. The reticular activating system (RAS) in the brainstem regulates consciousness and arousal. Damage to specific brainstem regions causes locked-in syndrome (conscious but paralyzed except eye movements). The brainstem is the last region to lose function in brain death.
- **Locus Coeruleus**: The locus coeruleus is a tiny nucleus in the pons that is the brain's sole source of norepinephrine. Despite its small size (~50,000 neurons), it projects throughout the brain and modulates arousal, attention, and stress responses. It's one of the first regions affected by Alzheimer's tau pathology, potentially explaining early attention deficits. LC-norepinephrine system is a target for ADHD and PTSD treatments.
- **Claustrum**: The claustrum is a thin, sheet-like structure that Francis Crick proposed as the 'conductor of consciousness' - integrating information from diverse cortical regions into unified conscious experience. It has connections with virtually all cortical areas. High density of 5-HT2A receptors (the target of psychedelics) suggests a role in altered states of consciousness. Its exact function remains one of neuroscience's biggest mysteries.
- **Nucleus Accumbens**: The nucleus accumbens is the brain's pleasure center, integrating dopamine signals from the VTA with glutamate inputs from the prefrontal cortex and amygdala. It's central to reward-seeking behavior and addiction. All addictive drugs increase dopamine in the nucleus accumbens. Deep brain stimulation of the nucleus accumbens is being tested for treatment-resistant depression and addiction.
- **Entorhinal Cortex**: The entorhinal cortex is the primary interface between the neocortex and hippocampus. Grid cells here create a hexagonal coordinate system for spatial navigation (Nobel Prize 2014). It's one of the first regions affected by Alzheimer's tau pathology, years before symptoms appear. This makes it a target for early Alzheimer's detection and intervention.
- **Pineal Gland**: The pineal gland produces melatonin from serotonin in response to darkness, regulating the circadian rhythm. Descartes famously called it the 'seat of the soul.' Pineal calcification increases with age and is visible on CT scans. Melatonin supplements are widely used for jet lag and insomnia. The pineal gland's role in circadian health is increasingly recognized as critical for overall wellbeing.
- **Ventromedial Prefrontal Cortex (vmPFC)**: The vmPFC is critical for integrating emotional signals into decision-making. Patients with vmPFC damage (e.g., Phineas Gage) show impaired judgment despite intact intellect. The vmPFC is central to fear extinction learning and is a target for anxiety disorder treatments. In 2025-2026, BCI research has explored vmPFC stimulation for treatment-resistant depression and anxiety.
- **Posterior Parietal Cortex (PPC)**: The PPC integrates sensory information to create spatial representations and guide movement. It's a key BCI target for prosthetic control, as PPC neurons encode movement intentions before execution. BrainGate and other BCI groups have demonstrated that PPC recordings can decode intended reach directions, enabling thought-controlled robotic arms. The PPC is also central to attention networks.
- **Ventral Tegmental Area (VTA)**: The VTA is the brain's primary source of dopamine neurons projecting to the nucleus accumbens (mesolimbic pathway) and prefrontal cortex (mesocortical pathway). It's central to reward prediction error and reinforcement learning. VTA dysfunction underlies addiction (drugs hijack VTA dopamine signaling) and depression (reduced reward sensitivity). Deep brain stimulation of VTA-connected circuits is being explored for treatment-resistant depression.
- **Retrosplenial Cortex**: The retrosplenial cortex is critical for spatial navigation and converting between egocentric and allocentric reference frames. It's one of the first regions to show atrophy in Alzheimer's disease, often before hippocampal degeneration. This makes it a potential early biomarker for AD. The retrosplenial cortex works closely with the hippocampus and entorhinal cortex in the brain's navigation and memory system.
- **Claustrum**: The claustrum is a thin, sheet-like structure that Francis Crick famously proposed as the 'conductor of consciousness' due to its extensive connectivity with nearly all cortical areas. Recent research (2025-2026) supports its role in integrating information across brain regions and coordinating conscious experience. Electrical stimulation of the claustrum can disrupt consciousness, and claustrum dysfunction is implicated in epilepsy and disorders of consciousness.
- ... and 42 more

### bci

- **Neuralink N1**: Neuralink的N1植入物包含1024个电极，通过手术机器人植入运动皮层。2024年首位人类受试者Noland Arbaugh通过意念控制电脑光标和玩游戏。2025年第二位受试者展示了改进的信号稳定性。Neuralink正在开发视觉假体（Blindsight）和语音解码功能。2026年里程碑：BCI已从辅助医疗设备转向更广泛的应用探索。
- **BrainGate**: BrainGate是学术界最成熟的侵入式BCI，使用Utah阵列植入运动皮层。斯坦福团队2023年实现了95字/分钟的语音解码速度（接近正常语速150字/分钟）。BrainGate还演示了通过意念控制机械臂抓取物体。长期稳定性是主要挑战。
- **Synchron Stentrode**: Synchron的Stentrode通过颈静脉植入，无需开颅手术。它附着在血管壁上记录运动皮层信号。2023年患者通过Stentrode实现了Apple Vision Pro控制。Synchron获得了FDA Breakthrough Device认定。2026年，Synchron正在探索与AI的深度集成，让BCI用户通过思维直接调用AI助手。
- **Emotiv EPOC X**: Emotiv EPOC X是最广泛使用的消费级EEG头带，14通道湿电极。用于游戏、冥想辅助和情绪监测。虽然不能实现精确控制，但可以检测大致的认知状态（专注、放松、压力）。Emotiv还提供开发者SDK和云平台。
- **OpenBCI Cyton + Galea**: OpenBCI提供开源EEG硬件，Cyton板16通道，Galea头显结合EEG和fNIRS（功能性近红外光谱）。开源特性使其成为研究者和创客的首选。Galea是首个同时采集EEG和fNIRS数据的消费级设备。
- **Paradromics Connex Direct**: Paradromics的Connex Direct使用高密度微线阵列，提供65,536个记录通道——远超Neuralink的1024。目标是实现高带宽脑机通信，特别是语音解码（将思维直接转换为文字）。获得FDA Breakthrough Device认定。2025-2026年计划开始人体试验。
- **Blackrock Neurotech Neuralace**: Blackrock Neurotech是BCI领域的老牌公司，其Utah阵列已被用于BrainGate等研究数十年。Neuralace是新一代高密度阵列，提供10,000+通道。Blackrock的BCI系统已让多位瘫痪患者实现了光标控制和打字。2025年被收购后加速商业化。
- **NextMind (Apple收购)**: NextMind开发了一种小型EEG传感器，贴在后脑勺上读取视觉皮层信号，可以检测用户正在注视的物体并实现意念控制。Apple于2023年收购NextMind，预计将技术集成到Vision Pro和未来设备中。这可能是Apple进入BCI领域的第一步。
- **Meta wrist-worn EMG**: Meta于2019年收购CTRL-Labs，开发腕带式EMG传感器。它不直接读取大脑信号，而是读取从大脑传到手腕的运动神经信号，可以在手指移动之前就检测到意图。目标是实现AR/VR中的隐形输入——无需实际移动手指就能打字或控制设备。
- **NeuroPace RNS System**: NeuroPace RNS是FDA批准的首个响应式神经刺激器，植入颅骨内持续监测脑电活动，检测到癫痫发作前兆时自动发送电脉冲阻止发作。它是闭环BCI的先驱——不仅是记录，还能实时干预。正在探索扩展到抑郁症和强迫症治疗。
- **Neuralink Blindsight**: Neuralink的Blindsight项目旨在为盲人恢复视觉。通过在视觉皮层植入电极阵列，将摄像头图像转换为电刺激，让盲人感知光点和形状。获得FDA Breakthrough Device认定。目前只能提供低分辨率视觉（光点矩阵），但Neuralink计划逐步提高分辨率。
- **Science Corp (Max Hodak)**: Science Corp由Neuralink联合创始人Max Hodak创立，采用不同路径：通过眼内植入物结合光遗传学技术，将基因疗法和光电植入物结合来恢复视力。这种方法不需要开颅手术，而是通过眼科手术植入。Science Corp在2025年展示了令人印象深刻的动物实验结果。
- **Precision Neuroscience Layer 7**: Precision Neuroscience的Layer 7是一种薄膜微电极阵列，放置在大脑表面（硬膜下）而不穿透脑组织。这比Neuralink的穿透式植入更安全，可逆（可取出）。2025年在人体试验中成功记录了高分辨率脑信号。由前Neuralink工程师创立。
- **LumiMind LumiSleep**: LumiMind的LumiSleep在CES 2026上亮相，是首个提供实时听觉反馈的消费级EEG设备。它监测睡眠脑电波，在检测到浅睡眠时播放特定声音来促进深度睡眠。代表了消费级神经技术的新趋势——从监测走向干预。
- **Cognixion ONE**: Cognixion ONE是一款结合EEG和AR的BCI头显，专为ALS和瘫痪患者设计。用户通过脑电波控制AR界面进行交流，系统将意图转换为合成语音。获得FDA Breakthrough Device认定。它代表了非侵入式BCI在辅助通信领域的最前沿。
- **Intracortical Visual Prosthesis (Bionic Eye / Orion)**: Second Sight开发了Argus II视网膜植入物（已停产）和Orion视觉皮层植入物。Orion绕过眼睛和视神经，直接刺激视觉皮层，理论上可以帮助更多类型的盲人。公司经历了破产和重组，但Orion的临床数据证明了皮层视觉假体的可行性。
- **Synchron + AI Integration**: Synchron正在将BCI与AI语言模型深度集成，让用户通过思维直接调用AI助手。这不是简单的打字解码，而是让AI理解用户的意图并执行复杂任务。2026年，这种BCI+AI的融合被认为是下一代交互界面的方向——从'思维打字'进化到'思维对话'。
- **Neural Speech Decoding (Stanford/UCSF)**: 斯坦福和UCSF团队在语音解码方面取得重大突破。2023年，斯坦福团队实现了95字/分钟的解码速度；UCSF团队实现了情感语音合成（不仅解码文字，还保留语调情感）。这些成果让瘫痪患者重新'说话'成为可能，是BCI领域最令人兴奋的进展之一。
- **Closed-Loop DBS for Depression**: 闭环深部脑刺激（DBS）是BCI的另一种形态：植入电极监测特定脑区活动，检测到抑郁症状的神经标志物时自动刺激。UCSF团队2021年在Nature报告了首例成功案例。与开环DBS不同，闭环系统只在需要时刺激，更有效且副作用更少。
- **UNESCO Neurotechnology Ethics Standard**: UNESCO于2025年通过了全球首个神经技术伦理标准，呼吁各国确保神经技术保持包容性和可及性。该标准涉及神经权利（neurorights）保护，包括认知自由、精神隐私、心理完整性和平等获取。智利已将神经权利写入宪法。这是BCI和神经技术领域最重要的政策里程碑。
- **CAS CEBSIT Invasive BCI**: BCI
- **65,536-Electrode Wireless Subdural BCI**: BCI
- **Long-term Independent Intracortical BCI for ALS**: BCI
- **Bidirectional BCI for Walking Exoskeleton**: BCI
- **Neuralink High-Volume Production (2026)**: Neuralink announced high-volume production of brain-computer interface devices starting in 2026, with plans to move to an almost entirely automated surgical procedure. With $650 million in funding, Neuralink received FDA Breakthrough Device Designation for speech restoration technology targeting severe speech impairments. The company launched its first clinical trial in the Middle East (UAE-PRIME) and aims to scale production and automate surgeries by late 2026.
- **Paradromics Connexus Direct Data Interface**: Paradromics' Connexus Direct Data Interface entered clinical trials in November 2025, as reported by Nature. The device is designed to safely restore speech for people with severe motor impairments, positioning it as a direct rival to Neuralink. Paradromics uses a high-channel-count electrode array that can record from thousands of neurons simultaneously, enabling more detailed neural signal decoding for speech restoration.
- **Consumer EEG BCI Wave (2026)**: Consumer brain-computer interfaces gained significant momentum in 2026, with EEG-based devices like Neurable's licensed headset and Emotiv's platforms reaching market. The FDA has granted breakthrough device designations to multiple BCI companies, accelerating the path to market. Consumer BCIs focus on gaming, focus training, sleep monitoring, and cognitive assessment, representing the non-invasive counterpart to clinical implantable BCIs.
- **Ultrasound-Based Neuromodulation BCI**: Non-invasive focused ultrasound neuromodulation is hitting an inflection point in 2026 as FDA approvals advance and the technology moves from hype to clinical reality. Unlike EEG-based BCIs that only read brain signals, ultrasound neuromodulation can both read and write neural activity non-invasively by focusing acoustic energy on specific brain regions. This bidirectional capability makes it a potential game-changer for treating depression, OCD, and chronic pain without surgery.
- **Flexible Electrode BCI (2026 Trend)**: Flexible electrode technology is a defining trend in BCI in 2026. The maturation of flexible neural electrode materials that minimize tissue scarring is enabling longer-lasting, more stable neural recordings. Neuralink's polymer threads and Synchron's stentrode both benefit from flexible electrode advances. This trend is critical for making BCIs viable as long-term medical devices rather than short-term research tools.
- **Brain Implants for Mental Health (2026 Trend)**: A major trend to watch in 2026 is the application of brain implants for mental health conditions. Beyond paralysis and speech restoration, researchers are exploring BCI and neuromodulation implants for treatment-resistant depression, OCD, PTSD, and addiction. This represents a significant expansion of BCI applications from motor restoration to psychiatric treatment, raising both therapeutic promise and ethical considerations about brain intervention for behavioral conditions.
- ... and 38 more

### neural_implants

- **Neuralink N1 Implant**: Neuralink N1是当前最受关注的神经植入物。1,024个电极分布在96根柔性聚合物线上，由R1手术机器人精确植入运动皮层。2024年首位人类受试者Noland Arbaugh成功通过意念控制电脑光标。N1采用无线充电和蓝牙传输，完全植入皮下，无外部连线。约硬币大小。
- **Utah Array (Blackrock)**: Utah阵列是BCI研究中最常用的侵入式电极，已有20+年人体使用经验。每根硅微针尖端镀铂记录单个神经元。缺点：刚性硅可能导致组织损伤和胶质疤痕；长期稳定性受限（信号质量随时间下降）。仍是学术研究的金标准。
- **Stentrode (Synchron)**: Stentrode是唯一不需要开颅手术的侵入式BCI植入物。它通过导管经颈静脉送入大脑血管，在运动皮层附近的血管壁上展开，记录皮层信号。这种微创植入方式大大降低了手术风险，是BCI走向临床普及的关键突破。
- **ECoG Strip/Grid**: ECoG（皮层脑电图）电极是癫痫手术前定位的标准工具，放置在大脑表面（硬膜下）记录皮层活动。与穿透式电极不同，ECoG不损伤脑组织，信号质量介于EEG和皮层内记录之间。高密度ECoG正在成为BCI研究的重要工具。
- **Precision Neuroscience Layer 7**: Precision的Layer 7是一种超薄柔性薄膜微电极阵列，放置在大脑表面而不穿透脑组织。关键优势：可逆——可以通过微创手术取出。这解决了侵入式BCI最大的顾虑之一（永久植入）。2025年人体试验显示信号质量接近穿透式电极。
- **NeuroPace RNS Neurostimulator**: NeuroPace RNS是FDA批准的首个闭环神经刺激器。植入颅骨内，持续监测脑电活动，检测到癫痫发作模式时自动发送电脉冲阻止发作。它是'读取+写入'双向BCI的先驱。电池寿命约8年，可通过无线充电更新算法。
- **DBS Electrodes (Medtronic, Abbott, Boston Scientific)**: 深部脑刺激（DBS）是最成熟的神经植入技术，已治疗20万+患者。新一代方向性电极可定向刺激特定脑区，减少副作用。Medtronic Percept具备感知功能（闭环DBS基础）。DBS正在扩展到抑郁症、阿尔茨海默病和成瘾治疗。
- **Cochlear Implant**: 人工耳蜗是最成功的神经假体，已植入100万+患者。它绕过受损的毛细胞，直接刺激听神经。虽然提供的是'电子听觉'（不如自然听力），但让聋人能够理解语言。它是BCI和神经植入技术的成功先例，证明了大脑可以适应人工输入。
- **Retinal Implant (Argus II / PRIMA)**: 视网膜植入物为视网膜疾病导致的盲人恢复部分视觉。Argus II是首个FDA批准的视网膜假体（60电极，已停产）。Pixium Vision的PRIMA使用光伏像素（378个），由外部眼镜投射红外光供电，无需体内电池。视觉分辨率仍然很低（光点矩阵），但在持续改进。
- **Vagus Nerve Stimulator (VNS)**: 迷走神经刺激器通过刺激迷走神经调节大脑活动。植入式VNS（LivaNova）用于癫痫和抑郁症；非植入式（electroCore gammaCore）用于偏头痛和簇状头痛。VNS的抗炎作用正在被探索用于自身免疫疾病。迷走神经是脑-体通信的主要通道。
- **Spinal Cord Stimulator**: 脊髓刺激器在脊髓硬膜外腔植入电极，发送电脉冲干扰疼痛信号传导至大脑。新一代设备采用高频刺激（10kHz, Nevro）和闭环感知（Evoke, Saluda）。脊髓刺激器是神经调控领域仅次于DBS的成功案例。
- **NeuroVista Seizure Advisory System**: NeuroVista系统持续监测脑电活动，在癫痫发作前数分钟至数小时发出预警。临床试验显示预警准确率可达80%以上。虽然公司已停止运营，但技术概念被其他公司继承。癫痫预警是闭环神经植入的重要应用方向。
- **Paradromics Connexus Implant**: Paradromics的Connexus植入物进入临床试验阶段，被Nature报道为可能挑战Neuralink的脑植入物。该设备使用高通道数电极阵列，可同时记录数千个神经元的活动，专门设计用于恢复严重运动障碍患者的语音沟通能力。与Neuralink的柔性聚合物电极不同，Paradromics采用更传统的高密度电极阵列技术。
- **LumiMind LumiSleep (CES 2026)**: LumiMind的LumiSleep在CES 2026上发布，是首个提供即时听觉反馈以促进睡眠过渡的消费级EEG设备。该设备通过实时监测脑电活动，在用户入睡过程中提供个性化的声音反馈，帮助加速入睡。LumiSleep代表了消费级神经技术从简单的脑电监测向主动干预的转变。
- **Guardian 4 Ear-EEG Earbuds**: CES 2026展示了新一代耳内EEG设备，如Guardian 4耳塞，配合认知智能平台将耳内EEG信号转化为认知指标。耳内EEG的优势在于佩戴舒适、日常可用，且耳道内电极信号质量优于额头EEG。这类设备代表了神经技术从专业医疗向日常消费级应用的过渡。
- **Closed-Loop Epilepsy Implant (Next Generation)**: 新一代闭环癫痫植入物结合了改进的信号检测算法和更精确的刺激参数。NeuroPace的RNS系统是已获FDA批准的闭环癫痫设备，2025-2026年的改进版本利用机器学习算法提高发作预测准确率，缩短检测-刺激延迟，并减少误触发。闭环神经植入是神经调控领域最具前景的方向之一。
- **Neuralink Mass Production Implant (2026)**: Elon Musk announced that Neuralink will begin high-volume production of brain-computer implants in 2026, with an almost entirely automated surgical procedure. The transition from manual to automated surgery is critical for scaling BCI deployment beyond a handful of research subjects. Neuralink also received FDA Breakthrough Device Designation for its speech restoration technology targeting severe speech impairments.
- **Columbia Silicon-on-Brain Implant**: Columbia University researchers announced a new generation of brain-computer interface using silicon chips placed on the brain surface. This approach differs from Neuralinks penetrating electrodes by using surface-mounted silicon arrays that reduce tissue damage while maintaining high signal quality. The silicon chip technology could transform human-computer interaction and expand treatment possibilities for neurological conditions.
- **Flexible Electrode Next Generation (2026)**: Flexible neural electrode materials that minimize tissue scarring have matured significantly by 2025-2026. This is one of the three key trends to watch in BCI in 2026 (per STAT News). New materials including hydrogel coatings, conductive polymers, and ultra-flexible substrates reduce the foreign body response and enable longer-term stable recordings. This addresses one of the fundamental challenges for chronic neural implants.
- **Paradromics Connex Implant**: Paradromics has entered clinical trials with its Connex implant, aiming to safely restore speech for people with severe communication impairments. Nature reported that this brain implant could rival Neuralinks. Paradromics uses a different electrode technology (microwire arrays) to achieve high-bandwidth neural recording. The clinical trial entry marks a significant milestone for BCI commercialization beyond Neuralink.
- **Focused Ultrasound Neuromodulation Device**: Non-invasive neurotech hits an inflection point in 2026 as focused ultrasound neuromodulation devices move from research to clinical applications. Unlike implanted electrodes, focused ultrasound can target deep brain structures (like the thalamus) without surgery. FDA approvals for ultrasound-based neuromodulation devices are expanding, making this a key technology to watch in the non-invasive BCI space.
- **Chinese BCI Implant (NEO System)**: Chinas domestic BCI implant programs are advancing rapidly, with the NEO system and other Chinese-developed implants entering human trials in 2025-2026. Chinas national BCI strategy aims for widespread use within 3-5 years. Chinese BCI companies benefit from state backing, faster regulatory pathways, and large patient populations for clinical trials, creating a competitive alternative to US-based BCI companies.
- **China NMPA-Approved BCI Implant for Quadriplegia**: China's NMPA approved the world's first BCI medical device in March 2026, specifically for patients with cervical spinal cord injury resulting in quadriplegia. The implant enables hand grasping function restoration. This regulatory milestone is significant because it represents the first time any regulatory body has approved a BCI implant as a medical device, potentially accelerating BCI commercialization globally.
- **Neuralink Automated Surgical Robot (2026)**: Neuralink is developing an almost entirely automated surgical procedure for its N1 brain implant, targeting near-full automation by late 2026. The R1 surgical robot currently assists human surgeons in implanting the ultra-thin polymer electrode threads. Full automation is critical for scaling BCI deployment beyond a handful of research subjects to thousands or millions of patients. This represents a key step in making BCI implantation as routine as other neurosurgical procedures.
- **Optogenetic Retinal Implant (Science Corp Advances)**: Science Corp, founded by Neuralink co-founder Max Hodak, is advancing optogenetic retinal implants that combine gene therapy with optoelectronic devices. Unlike cortical visual prostheses (Neuralink Blindsight), Science Corp's approach targets the retina directly, requiring only ophthalmic surgery rather than craniotomy. The gene therapy makes retinal ganglion cells light-sensitive, and the implant provides patterned light stimulation. This approach could restore vision to patients with retinal degeneration without the risks of brain surgery.
- **Nonsurgical Cell-Electronics Brain Interface**: A nonsurgical brain implant enabled through a cell-electronics interface was published in Nature Biotechnology 2025. Bioelectronic implants for brain stimulation traditionally require invasive surgery, but this new approach uses engineered cells that integrate with neural tissue and communicate with external electronics. This could transform brain stimulation treatments by eliminating the need for craniotomy, making neuromodulation accessible to a much broader patient population.
- **Extended-Lifespan Neural Implant Coating**: A new coating technology significantly extends the lifespan of neural implants in the body. The findings demonstrate that bare-die silicon chips, when carefully designed with this coating, can operate reliably in the body for months rather than weeks. This addresses the fundamental challenge of the foreign body response that degrades signal quality over time in chronic neural implants. The coating could dramatically improve BCI device longevity and reliability.
- **Neuralink Automated Surgical Robot (2026 Target)**: Neuralink is developing an automated surgical robot for near-fully automated implantation of its N1 Implant. Elon Musk announced on December 31, 2025 that Neuralink would start high-volume production of brain-computer interfaces in 2026. The automated surgical system is key to scaling BCI deployment beyond specialized neurosurgical centers.
- **Columbia Silicon BCI Chip**: Columbia University developed a next-generation silicon-based BCI chip that advances the state of the art in neural recording technology. The chip uses advanced silicon microfabrication techniques to achieve high-density electrode arrays with improved signal quality and longevity compared to traditional microelectrode arrays.
- **China NEO System (Human Trials)**: China's NEO (Neural Electronic Opportunity) system is a minimally invasive epidural BCI in human trials. The system uses flexible electrode arrays placed above the dura mater, avoiding direct brain tissue penetration. The NEO system is part of China's national BCI strategy and represents an alternative approach to fully invasive systems like Neuralink.
- ... and 7 more

### brain_disorders

- **Alzheimer's Disease**: Alzheimer's is the most common cause of dementia, characterized by progressive memory loss and cognitive decline. Amyloid plaques and tau tangles accumulate decades before symptoms. Leqembi and Kisunla (anti-amyloid antibodies) are the first disease-modifying treatments, slowing decline by ~27-35%. Early detection via blood tests (p-tau217) is transforming diagnosis. BCI and neurotechnology approaches include deep brain stimulation and cognitive prosthetics.
- **Parkinson's Disease**: Parkinson's results from loss of dopamine neurons in the substantia nigra. Motor symptoms (tremor, rigidity, bradykinesia) appear after ~60% neuron loss. DBS is the most effective surgical treatment. New approaches include focused ultrasound (MRgFUS) for tremor, gene therapy (AADC gene), and stem cell transplantation. BCI research is exploring closed-loop DBS that adapts to symptom fluctuations.
- **Major Depressive Disorder (MDD)**: Depression is the leading cause of disability worldwide. While SSRIs help many, ~30% have treatment-resistant depression (TRD). Ketamine/esketamine provides rapid relief (hours vs weeks for SSRIs). TMS is FDA-approved for TRD. Psilocybin-assisted therapy shows remarkable results in clinical trials. Closed-loop DBS targeting the subcallosal cingulate is being developed for severe TRD.
- **Schizophrenia**: Schizophrenia involves positive symptoms (hallucinations, delusions), negative symptoms (apathy, social withdrawal), and cognitive deficits. The dopamine hypothesis explains positive symptoms; glutamate/NMDA dysfunction may underlie cognitive deficits. Clozapine is most effective for treatment-resistant cases but has serious side effects. New muscarinic agonists (KarXT) show promise.
- **Autism Spectrum Disorder (ASD)**: ASD is characterized by social communication difficulties and restricted/repetitive behaviors. Brain imaging shows atypical connectivity patterns and early brain overgrowth. No medications treat core symptoms; current drugs only address associated symptoms (irritability, ADHD). TMS and neurofeedback are being explored. The neurodiversity movement advocates for acceptance rather than 'cure.'
- **Epilepsy**: Epilepsy is characterized by recurrent seizures. ~30% of patients are drug-resistant. Neurotechnology plays a major role: NeuroPace RNS (closed-loop stimulation), DBS (open-loop), VNS, and laser ablation (Visualase). AI-powered seizure prediction is advancing rapidly. BCI approaches aim to detect and abort seizures before they occur.
- **Stroke**: Stroke is the second leading cause of death and a major cause of disability. Thrombectomy (mechanical clot removal) has revolutionized acute treatment. BCI and neurotechnology are advancing stroke rehabilitation: TMS to enhance plasticity, BCI-driven robotic therapy, and vagus nerve stimulation paired with rehabilitation to promote motor recovery.
- **Traumatic Brain Injury (TBI)**: TBI ranges from mild concussion to severe injury. Repeated concussions can cause CTE (chronic traumatic encephalopathy), seen in athletes and military personnel. Blood biomarkers (GFAP, UCH-L1) are improving diagnosis. Neurotechnology approaches include EEG-based concussion assessment, TMS for post-concussion symptoms, and BCI for severe TBI rehabilitation.
- **PTSD (Post-Traumatic Stress Disorder)**: PTSD involves persistent re-experiencing, avoidance, and hyperarousal after trauma. Neurobiologically, the amygdala is hyperactive while the prefrontal cortex fails to regulate it. MDMA-assisted therapy (MAPS) achieved breakthrough results in Phase 3 trials and is expected to receive FDA approval. This would be the first psychedelic-assisted therapy approved for PTSD.
- **ALS (Amyotrophic Lateral Sclerosis)**: ALS causes progressive degeneration of motor neurons, leading to paralysis while cognition often remains intact. BCI is critically important for ALS patients to maintain communication as the disease progresses. BrainGate and Neuralink have enrolled ALS patients. New treatments include antisense oligonucleotides (Qalsody for SOD1-ALS) and combination therapy (Relyvrio).
- **Multiple Sclerosis (MS)**: MS is an autoimmune disease where the immune system attacks myelin (insulation around nerve fibers). 20+ disease-modifying therapies are available, transforming prognosis. B-cell depletion (ocrelizumab) is effective for both relapsing and progressive forms. Hematopoietic stem cell transplantation (HSCT) can halt disease in aggressive cases. Neurotechnology aids in monitoring and rehabilitation.
- **Addiction / Substance Use Disorder**: Addiction hijacks the brain's reward system, with dopamine-driven compulsive drug-seeking despite consequences. The nucleus accumbens and VTA are central. Medication-assisted treatment (MAT) is the gold standard for opioid use disorder. DBS of the nucleus accumbens is being tested for severe, treatment-resistant addiction. TMS targeting the insula and prefrontal cortex shows promise for reducing craving.
- **Chronic Pain**: Chronic pain involves maladaptive neuroplastic changes in pain processing networks. Central sensitization amplifies pain signals. Spinal cord stimulation and dorsal root ganglion (DRG) stimulation are neurotechnology approaches for refractory pain. DBS targeting the periventricular/periaqueductal gray is used for severe neuropathic pain. Non-invasive approaches include TMS and neurofeedback.
- **Huntington's Disease**: Huntington's is a fatal genetic neurodegenerative disease caused by CAG repeat expansion in the HTT gene. Symptoms include chorea (involuntary movements), cognitive decline, and psychiatric symptoms. Gene-silencing approaches (antisense oligonucleotides by Roche/Ionis, RNAi by UniQure) aim to reduce mutant huntingtin protein. These trials represent the frontier of genetic neurotherapy.
- **Consciousness Disorders (Coma, Vegetative State, Minimally Conscious State)**: Disorders of consciousness range from coma to vegetative state (VS) to minimally conscious state (MCS). Brain imaging reveals that 15-20% of patients diagnosed as vegetative may have covert consciousness (cognitive motor dissociation). Neurotechnology approaches include DBS of the thalamus, VNS, and focused ultrasound thalamic stimulation. BCI-like paradigms using fMRI help detect covert consciousness.
- **Treatment-Resistant Depression (TRD)**: Treatment-resistant depression affects approximately 30% of the 300+ million people with depression worldwide. In 2025-2026, new approaches include psilocybin-assisted therapy, deep brain stimulation of the subgenual cingulate, and esketamine. BCI and neuromodulation implants for TRD are an emerging trend in 2026.
- **Post-Concussion Syndrome / Chronic Traumatic Encephalopathy (CTE)**: CTE is a neurodegenerative disease caused by repeated head impacts, confirmed in approximately 90% of former NFL players studied. In 2025-2026, advances in blood biomarkers (p-tau) and neuroimaging are enabling earlier detection.
- **Autism Spectrum Disorder (ASD)**: Autism spectrum disorder is increasingly understood as a difference in brain connectivity rather than a simple deficit. 2025-2026 research reveals both hyper-connectivity in some networks and hypo-connectivity in others. Neuromodulation approaches and digital therapeutics are emerging treatment options.
- **Long COVID Neurological Syndrome**: Long COVID neurological syndrome affects millions worldwide with persistent cognitive impairment (brain fog), memory problems, loss of smell, and autonomic dysfunction. 2025-2026 research reveals persistent neuroinflammation, microglial activation, and blood-brain barrier disruption as key mechanisms. Neuromodulation approaches including TMS and tDCS are being tested for cognitive rehabilitation.
- **Traumatic Brain Injury (TBI) - Chronic Effects**: Chronic effects of traumatic brain injury include persistent cognitive deficits, emotional changes, and increased risk of chronic traumatic encephalopathy (CTE). 2025-2026 research focuses on biomarkers for CTE (anti-tau PET imaging), neuromodulation for cognitive rehabilitation, and the connection between repeated concussion and neurodegeneration. BCI technology is being explored for cognitive enhancement in chronic TBI patients.
- **Consciousness Disorders (Coma, Vegetative State, Minimally Conscious State)**: Disorders of consciousness including coma, vegetative state, and minimally conscious state represent a frontier for neuroscience and BCI technology. 2025-2026 advances include: thalamic DBS for consciousness restoration, focused ultrasound targeting the thalamus non-invasively, and BCI-based communication with minimally conscious patients. The claustrums role as a consciousness integrator is being explored as a therapeutic target.
- **Treatment-Resistant Depression (TRD)**: Treatment-resistant depression affects approximately 30% of depression patients and is a major focus of neuromodulation and BCI research in 2025-2026. Brain implants for mental health are a key trend, with closed-loop neuromodulation systems detecting depression biomarkers and delivering targeted stimulation. Psilocybin-assisted therapy has shown remarkable results in Phase 2/3 trials for TRD.
- **Treatment-Resistant Depression (BCI/DBS Target)**: Treatment-resistant depression (TRD) affects approximately 30% of depression patients who fail to respond to at least two antidepressant treatments. UCSF demonstrated that closed-loop deep brain stimulation can effectively treat TRD by monitoring biomarkers of depression and stimulating only when needed. BCI neurofeedback is also emerging as a non-invasive approach. TRD is a key target for the 2026 trend of brain implants for mental health, representing a major unmet medical need.
- **Post-Traumatic Stress Disorder (PTSD) - Neuromodulation**: PTSD is characterized by amygdala hyperactivity, medial prefrontal cortex hypoactivity, and hippocampal changes. Neuromodulation approaches including TMS and focused ultrasound are being explored to normalize these circuits. MDMA-assisted therapy has shown remarkable results in Phase 3 trials and is approaching FDA approval. The combination of pharmacotherapy with neuromodulation represents a new frontier in PTSD treatment.
- **Autism Spectrum Disorder (ASD) - Connectomics Insights**: Autism Spectrum Disorder is increasingly understood through connectomics, with the MICrONS project and other brain mapping efforts revealing circuit-level abnormalities. The cerebellum has emerged as a key region, with Purkinje cell loss consistently observed in ASD brains. The social brain network (amygdala, fusiform gyrus, temporoparietal junction) shows atypical connectivity. While no pharmacological treatments exist for core ASD symptoms, connectomics-driven insights are guiding the development of targeted neuromodulation approaches.
- **Concussion / Mild Traumatic Brain Injury (mTBI)**: Concussion (mild traumatic brain injury) is a major health concern, particularly in sports. EEG-based concussion assessment devices are gaining regulatory approval in 2025-2026, enabling rapid sideline assessment of brain function after head impacts. These devices measure changes in brain wave patterns associated with concussion, providing objective data to supplement clinical evaluation. The consumer EEG device wave (CES 2026) is also enabling at-home monitoring of post-concussion recovery.
- **Addiction (Substance Use Disorders) - Neuromodulation**: Addiction is increasingly understood as a brain circuit disorder involving the mesolimbic dopamine pathway (VTA to nucleus accumbens), prefrontal cortex (impaired impulse control), and insula (craving). TMS targeting the prefrontal cortex is FDA-approved for smoking cessation, and DBS of the nucleus accumbens is in clinical trials for severe alcohol and opioid addiction. The 2026 trend of brain implants for mental health includes addiction as a key target, particularly as the opioid crisis continues.
- **Bipolar Disorder (Neuromodulation Approaches)**: Bipolar disorder involves dramatic mood swings between mania and depression. Lithium remains the gold standard treatment but has significant side effects. In 2025-2026, neuromodulation approaches including DBS and TMS are being explored for treatment-resistant bipolar depression. Closed-loop DBS that detects mood state transitions and delivers targeted stimulation is a promising research direction. The disorder involves dysregulation of prefrontal-amygdala circuits.
- **Treatment-Resistant Depression (Closed-Loop DBS Target)**: Treatment-resistant depression is a severe form of major depression that does not respond to conventional antidepressants. UCSF researchers demonstrated that closed-loop DBS of Area 25 can produce sustained remission. This has become a primary target for next-generation neuromodulation, with multiple clinical trials ongoing in 2025-2026 exploring adaptive stimulation strategies.
- **PTSD (Neuromodulation Therapy Target)**: PTSD is increasingly targeted by neuromodulation therapies including TMS and focused ultrasound. MDMA-assisted therapy completed Phase 3 trials with statistically significant reductions in PTSD symptoms. psilocybin-assisted therapy is also in clinical trials. These neuromodulation and psychedelic approaches represent a paradigm shift from traditional pharmacotherapy.
- ... and 8 more

### neuropharmacology

- **Psilocybin-Assisted Therapy**: Psilocybin is the most studied psychedelic for therapeutic use. It acts on 5-HT2A receptors, dramatically increasing brain connectivity and disrupting the default mode network (associated with rumination in depression). Clinical trials show 1-3 sessions with psychological support can produce lasting antidepressant effects (months to years). Compass Pathways and Usona Institute are leading Phase 2/3 trials. Expected FDA decision by 2026-2027.
- **MDMA-Assisted Therapy (MAPS)**: MDMA-assisted therapy is the closest psychedelic to FDA approval. MAPS Phase 3 trials showed 67% of PTSD patients no longer met diagnostic criteria after 3 sessions. MDMA doesn't cause hallucinations but enhances emotional openness and trust, making trauma processing possible. Expected to be the first legally approved psychedelic-assisted therapy, potentially in 2025-2026.
- **Ketamine / Esketamine (Spravato)**: Ketamine is the first rapid-acting antidepressant, working within hours (vs weeks for SSRIs). It blocks NMDA receptors, triggering a glutamate surge that promotes synaptogenesis (new neural connections). Esketamine (Spravato) nasal spray is FDA-approved for TRD and suicidal ideation. IV ketamine clinics are widespread. Main limitations: short duration (days-weeks), abuse potential, dissociative side effects.
- **Neuroplastogens (Non-Hallucinogenic Psychedelics)**: Neuroplastogens are a new class of drugs that aim to capture the therapeutic benefits of psychedelics (neuroplasticity, anti-depressant effects) without the hallucinogenic experience. By selectively activating specific 5-HT2A signaling pathways (β-arrestin vs Gq), these compounds promote neural growth and reconnection without causing perceptual disturbances. This could make psychedelic-inspired therapy much more accessible and scalable.
- **Anti-Amyloid Antibodies (Leqembi, Kisunla)**: Leqembi and Kisunla are the first disease-modifying treatments for Alzheimer's, slowing cognitive decline by 27-35% over 18 months by clearing amyloid plaques. They're effective only in early-stage AD. Side effects include ARIA (amyloid-related imaging abnormalities, brain swelling/bleeding) in ~20-30% of patients. IV infusion every 2-4 weeks. Cost: ~$26,000/year. Blood tests (p-tau217) are enabling earlier diagnosis and treatment.
- **Antisense Oligonucleotides (ASOs) for Neurological Diseases**: ASOs represent a paradigm shift: targeting the genetic root cause rather than symptoms. Nusinersen (Spinraza) transformed SMA from a fatal childhood disease to a manageable condition. Tofersen (Qalsody) slows SOD1-ALS progression. ASOs for Huntington's (reducing mutant huntingtin) are in clinical trials. The challenge: intrathecal delivery (spinal injection) and blood-brain barrier penetration.
- **GLP-1 Receptor Agonists (Neuroprotection)**: GLP-1 receptor agonists (originally for diabetes/obesity) show remarkable neuroprotective properties. Large observational studies found 40-60% reduced dementia risk in GLP-1 users. Phase 3 trials for Alzheimer's (semaglutide) and Parkinson's are ongoing. Mechanisms include reducing neuroinflammation, improving mitochondrial function, and promoting neurogenesis. If confirmed, this would repurpose one of the most prescribed drug classes for brain protection.
- **Ketamine Analogues / Next-Gen Rapid Antidepressants**: Multiple companies are developing ketamine-like drugs with improved safety profiles: no dissociative effects, no abuse potential, oral administration. Rel-1017 (dextromethadone) showed rapid antidepressant effects in Phase 2. The goal is to capture ketamine's rapid efficacy while eliminating its drawbacks (dissociation, abuse potential, need for IV administration/monitoring).
- **Cannabis-Based Neuropharmacology (CBD/THC)**: Cannabis-based therapeutics are expanding beyond Epidiolex (CBD for rare epilepsies). CBD's anxiolytic and antipsychotic effects are being studied for PTSD and schizophrenia. Selective CB1/CB2 modulators aim to provide therapeutic benefits without the 'high.' The endocannabinoid system is a major target for pain, inflammation, and psychiatric disorders.
- **Gene Therapy for Neurological Diseases (AAV Vectors)**: AAV gene therapy delivers functional genes to brain cells. Zolgensma (AAV9-SMN1) is a one-time cure for SMA type 1. AAV-AADC delivers the aromatic L-amino acid decarboxylase gene to Parkinson's patients' putamen, enhancing dopamine production. Challenges include immune responses to AAV, blood-brain barrier penetration, and manufacturing costs ($2.1M for Zolgensma).
- **Focused Ultrasound + Microbubbles (BBB Opening)**: Focused ultrasound with microbubbles can transiently open the blood-brain barrier (BBB), the biggest obstacle to brain drug delivery. This allows antibodies, gene therapies, and chemotherapy to reach the brain in therapeutic concentrations. In Alzheimer's trials, BBB opening itself appears to promote amyloid clearance by allowing microglia access. This technology could transform neuropharmacology by making previously ineffective drugs work.
- **Digital Therapeutics (DTx) for Neurological/Psychiatric Conditions**: Digital therapeutics are FDA-authorized software programs that treat neurological and psychiatric conditions through neuroplasticity. EndeavorRx is the first FDA-authorized video game treatment (for ADHD). Freespira uses breathing biofeedback for PTSD. DTx represents the intersection of neuropharmacology and neurotechnology—software that changes brain function without drugs.
- **Neuroplastogens (Non-Hallucinogenic Psychedelics)**: Neuroplastogens are a new class of compounds that promote neuroplasticity through 5-HT2A receptor activation but without the hallucinogenic effects of traditional psychedelics. Multiple companies are developing neuroplastogens, with some entering Phase 1 trials in 2025-2026.
- **Psychedelic Polypharmacology Discovery**: A landmark 2025 study revealed that psychedelics have potent and efficacious actions at nearly every serotonin, dopamine, and adrenergic receptor — far beyond the previously assumed 5-HT2A selectivity. This polypharmacology is reshaping drug design strategies for next-generation psychedelic-inspired therapeutics.
- **MDMA-Assisted Therapy (Post-FDA Review)**: MDMA-assisted therapy for PTSD received a Complete Response Letter from the FDA in 2024, citing concerns about functional unblinding and adverse events. The psychedelic medicine community is learning from this setback, with improved trial designs expected for resubmission.
- **Anti-Tau Immunotherapy for Neurodegeneration**: Anti-tau immunotherapy targets the spread of tau neurofibrillary tangles, a hallmark of Alzheimer and other tauopathies. Unlike anti-amyloid therapies that target plaques, anti-tau approaches address the pathology most closely correlated with cognitive decline. Several candidates are in Phase 2/3 trials in 2025-2026.
- **MDMA-Assisted Therapy (PTSD)**: MDMA-assisted therapy for PTSD has completed Phase 3 trials with remarkable results. MAPS-sponsored studies show that 67-71% of participants no longer meet PTSD diagnostic criteria after three MDMA-assisted therapy sessions. The FDA advisory committee meeting in 2024 raised procedural concerns but the therapy remains on track for potential approval. MDMA enhances the therapeutic alliance by reducing fear and increasing trust.
- **5-HT2A Partial Agonists (Next-Gen Psychedelics)**: Next-generation psychedelic-inspired compounds aim to deliver the neuroplasticity benefits of psychedelics without the hallucinogenic experience. These 5-HT2A partial agonists (psychoplastogens) promote rapid dendritic growth and synaptogenesis similar to psilocybin but without causing a trip. This could make psychedelic-derived therapies more scalable and acceptable for widespread clinical use.
- **GLP-1 Receptor Agonists for Neurodegeneration**: GLP-1 receptor agonists (originally developed for diabetes and obesity) are being repurposed for neurodegenerative diseases. Observational data from millions of users shows 40-60% reduced risk of dementia in GLP-1 RA users. Phase 2/3 trials are underway for Alzheimers and Parkinsons. The neuroprotective mechanism involves reducing neuroinflammation, improving mitochondrial function, and potentially reducing amyloid and tau pathology.
- **Gene Therapy for Neurological Diseases**: Gene therapy for neurological diseases is advancing rapidly in 2025-2026. Following the success of Zolgensma for SMA, gene therapies are in development for Parkinsons (AADC gene therapy), Alzheimers (anti-amyloid gene therapy), Huntingtons (HTT-lowering), and epilepsy (neurotransmitter-modulating gene therapy). The key challenge is delivering genes across the blood-brain barrier, with AAV9 and novel capsids showing promise.
- **MDMA-Assisted Therapy (PTSD)**: MDMA-assisted therapy has completed Phase 3 clinical trials for PTSD with remarkable results, showing that 67-71% of participants no longer met PTSD criteria after three sessions. MDMA promotes fear extinction and enhances the therapeutic alliance, allowing patients to process traumatic memories without being overwhelmed. FDA approval is expected in 2025-2026, which would make it the first psychedelic-assisted therapy approved for clinical use. MAPS (Multidisciplinary Association for Psychedelic Studies) has led the 30+ year effort.
- **Psilocybin-Assisted Therapy (Depression)**: Psilocybin-assisted therapy is advancing through clinical trials for treatment-resistant depression, with breakthrough therapy designations in both the US and UK. Psilocybin promotes neuroplasticity and reorganizes brain networks (particularly reducing DMN rigidity associated with depression). A single or few sessions can produce lasting antidepressant effects, unlike daily medication. COMPASS Pathways and Usona Institute are leading clinical development. Australia has already rescheduled psilocybin for clinical use.
- **Neuropharmacology + Neurotechnology Convergence (2026 Trend)**: A major 2026 trend is the convergence of neuropharmacology and neurotechnology. Drug-device combinations are showing synergistic effects: psychedelics combined with neurofeedback, DBS combined with pharmacotherapy, and TMS combined with cognitive enhancers. This convergence recognizes that brain disorders are circuit-level problems that may benefit from both chemical and electrical interventions. The combination approach could dramatically improve treatment outcomes for conditions that respond poorly to either approach alone.
- **Ketamine/Esketamine (Rapid-Acting Antidepressant)**: Ketamine and its S-enantiomer esketamine (Spravato) represent a breakthrough in rapid-acting antidepressants. Unlike conventional antidepressants that take weeks to work, ketamine can reduce depressive symptoms within hours. Esketamine nasal spray is FDA-approved for treatment-resistant depression and suicidal ideation. The mechanism involves NMDA receptor antagonism leading to rapid synaptic plasticity. However, concerns about abuse potential, dissociative side effects, and long-term safety remain.
- **Anti-Amyloid Antibodies (Alzheimer's Disease)**: Anti-amyloid antibodies lecanemab (Leqembi) and donanemab (Kisunla) are the first disease-modifying therapies for Alzheimer's disease, receiving FDA approval in 2023-2024. They slow cognitive decline by ~27-35% over 18 months by clearing amyloid-beta plaques. However, they carry risks of ARIA (amyloid-related imaging abnormalities) and are only effective in early-stage AD with confirmed amyloid pathology. These drugs represent a paradigm shift from symptomatic to disease-modifying treatment in neurodegeneration.
- **Psychedelic Polypharmacology Discovery (2025)**: A landmark 2025 study published in Neuron revealed that psychedelics have potent and efficacious actions at nearly every serotonin, dopamine, and adrenergic receptor — far beyond the previously assumed 5-HT2A selectivity. This polypharmacology discovery is reshaping drug design strategies for next-generation psychedelic-inspired therapeutics. The finding suggests that the therapeutic effects of psychedelics may involve multiple receptor systems simultaneously, not just 5-HT2A, which has major implications for developing non-hallucinogenic neuroplastogens.
- **Neuroplastogens: Next Wave Without the Trip (2026)**: The next wave of psychedelics focuses on brain rewiring without the trip. Neuroplastogens — non-hallucinogenic compounds that promote neuroplasticity through selective 5-HT2A receptor activation — are advancing through preclinical and early clinical development in 2026. By separating therapeutic neuroplasticity from hallucinations, these compounds could make psychedelic-inspired therapy much more scalable and accessible. Multiple companies including Delix Therapeutics and Mindstate Design Labs are developing candidates.
- **Psychedelic Polypharmacology Discovery (Neuron 2025)**: A landmark Neuron 2025 paper revealed that psychedelics have potent and efficacious actions at nearly every serotonin, dopamine, and adrenergic receptor subtype — far more targets than previously appreciated. This polypharmacology explains the complex subjective effects and suggests that different receptor profiles may be harnessed for different therapeutic outcomes. The discovery opens new avenues for rational psychedelic-inspired drug design.
- **Neuroplastogens: Next-Generation Non-Hallucinogenic Psychedelics**: Neuroplastogens are a new class of compounds that promote neural plasticity through 5-HT2A receptor activation without producing hallucinations. By separating therapeutic neuroplasticity from hallucinogenic effects, these molecules could make treatment safer and more accessible. 2026 is a key development year for this class, with several candidates advancing toward clinical trials.
- **GLP-1 Receptor Agonists for Neuroprotection**: GLP-1 receptor agonists (originally developed for diabetes and obesity) show remarkable neuroprotective properties. Observational studies report 40-60% reduced dementia risk in patients taking these drugs. The mechanism involves reducing neuroinflammation, promoting neuronal survival, and improving brain insulin signaling. Clinical trials for Alzheimer's prevention are being planned, potentially representing the largest drug repurposing opportunity in neurology.
- ... and 7 more

## Related Knowledge Bases

- [GeneTech](https://genetech.tools) - Gene therapy for neurological disorders
- [RobotParts](https://robot.genetech.tools) - Neuro-inspired robotics
- [AgentEco](https://agent.genetech.tools) - BCI-agent interfaces